

CLINICAL RESEARCH

Retina Associates of Utah is proud to partner with a variety of pharmaceutical companies to bring patients the newest innovations in retinal disease treatment. Currently, we are conducting nine (9) clinical studies with others in our research pipeline. From providing important safety and efficacy data for FDA approved Lucentis (monospecific anti-VEGF antibody), Susvimo (port delivery system aka implant) and Vabysmo (the first bispecific anti-VEGF antibody) to safely administering other novel therapies including gene therapy, RAU strives to serve patients in Utah with innovative treatments for wet and dry macular degeneration, diabetic macular edema, retinal vein occlusions, and more.

To learn more details about our clinical studies or to inquire about how to participate, please contact our research department (801) 312-2070.

Current Clinical Studies:

Atmosphere - Regenxbio Gene Therapy for Wet Macular Degeneration; currently enrolling

Portal - Port Delivery System with Lucentis (Susvimo) for Wet Macular Degeneration; closed enrollment, in active follow up

Pagoda - Port Delivery System with Lucentis (Susvimo) for Diabetic Macular Edema; close enrollment, in active follow up

Rhone-X - Faricimab (Vabysmo) intravitreal injection for Diabetic Macular Edema; closed enrollment, in active follow up

Avonelle-X - Faricimab (Vabysmo) intravitreal injection for Wet Macular Degeneration; closed enrollment, in active follow up

Ionis Golden - ISIS subcutaneous injection for Dry Macular Degeneration; currently enrolling

Gather2 - Gather2 intravitreal injection for Dry Macular Degeneration; closed enrollment, in active follow up

Balaton - Faricimab (Vabysmo) intravitreal injection for branch retinal vein occlusion; closed enrollment, in active follow up

Comino - Faricimab (Vabysmo) intravitreal injection for central retinal vein occlusion; closed enrollment, in active follow up

Studies in our Pipeline:

Ascent - Gene Therapy for Wet Macular Degeneration

Belvedere - Port Delivery System with Lucentis (Susvimo) for Wet Macular Degeneration

Shore - Anti-VEGF intravitreal injection for Wet Macular Degeneration

updated CK 02/22/2022